{"schema_version":"secwatch.filing_event.v1","accession":"0001736730-25-000072","form_type":"8-K","ticker":"CAMP","cik":"0001736730","company_name":"Camp4 Therapeutics Corp","filed_at":"2025-09-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.839713+00:00","generated_at":"2026-05-17T07:03:42.121950+00:00","sec_items":["1.01","3.02","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"CAMP4 Therapeutics announces up to $100M private placement and board changes","bullets":["Initial closing raises $50M from 26.7M shares at $1.53/share, pre-funded warrants, and management shares; total upfront proceeds ~$50M.","Second closing of up to $50M contingent on regulatory clearance for SYNGAP1 trial and stock price milestone or waiver.","Directors James Boylan, Ravi Thadhani, and Paula Ragan resigned; Doug Williams appointed Board Chair.","Daniel Tardiff elevated to Chief Scientific Officer effective October 1, 2025.","Financing led by Coastlands Capital with Janus Henderson, Balyasny, Vivo Capital, 5AM Ventures and others."],"urls":{"canonical":"https://secwatch.observer/filing/0001736730-25-000072","json":"https://secwatch.observer/filing/0001736730-25-000072.json","markdown":"https://secwatch.observer/filing/0001736730-25-000072.md","text":"https://secwatch.observer/filing/0001736730-25-000072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1736730/000173673025000072/0001736730-25-000072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1736730/000173673025000072/camp-20250909.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-17T07:03:42.121950+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"41e1ee188db99092f7b5a8354746ed1a17e1fa8d","claim":"Camp4 Therapeutics Corp issued 26,681,053 shares of common stock to certain accredited investors for $1.53 per Share.","evidence_excerpt":"At the Initial Closing, the Company has agreed to issue and sell 26,681,053 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), at an offering price of $1.53 per Share (the “ Share Price ”)","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1736730/000173673025000072/0001736730-25-000072-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"common stock"},{"label":"Shares","value":"26,681,053 shares"},{"label":"Purchaser","value":"certain accredited investors"},{"label":"Consideration","value":"$1.53 per Share"}],"fact_type":"equity_issuance"},{"claim_id":"9b698b61aa4863c1f71299fbde24791f01679eff","claim":"Camp4 Therapeutics Corp issued pre-funded warrants to purchase 6,003,758 shares of Common Stock of warrant to certain accredited investors for $1.5299 per pre-funded warrant.","evidence_excerpt":"in lieu of Common Stock to certain Investors, pre-funded warrants to purchase 6,003,758 shares of Common Stock (the “ Warrant Shares ” and, together with the Shares, the “ Securities ”) at an offering price of $1.5299 per pre-funded warrant (the “ Pre-Funded Warrant Price ”)","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1736730/000173673025000072/0001736730-25-000072-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"warrant"},{"label":"Shares","value":"pre-funded warrants to purchase 6,003,758 shares of Common Stock"},{"label":"Purchaser","value":"certain accredited investors"},{"label":"Consideration","value":"$1.5299 per pre-funded warrant"}],"fact_type":"equity_issuance"},{"claim_id":"bf706e9557376c3821be30fe06c946f4d62f1dfc","claim":"Camp4 Therapeutics Corp issued an additional 36,361 Shares of common stock to certain members of management including the Company’s CEO Josh Mandel-Brehm, the Company’s CFO Kelly Gold, the Company’s CMO Yuri Maricich, and the Company’s co-founders Richard Young and Leonard Zon for a purchase price of $1.65 per share.","evidence_excerpt":"the Company will issue and sell to certain members of management, including the Company’s CEO Josh Mandel-Brehm, the Company’s CFO Kelly Gold, the Company’s CMO Yuri Maricich, and the Company’s co-founders Richard Young, who also serves as a director on the Company’s Board of Directors (the “ Board ”) and Leonard Zon, who serves as a Board observer, an additional 36,361 Shares at a purchase price of $1.65 per share","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1736730/000173673025000072/0001736730-25-000072-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"common stock"},{"label":"Shares","value":"an additional 36,361 Shares"},{"label":"Purchaser","value":"certain members of management including the Company’s CEO Josh Mandel-Brehm, the Company’s CFO Kelly Gold, the Company’s CMO Yuri Maricich, and the Company’s co-founders Richard Young and Leonard Zon"},{"label":"Consideration","value":"a purchase price of $1.65 per share"}],"fact_type":"equity_issuance"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}